Phase II study of modified S-1, docetaxel and cisplatin combination chemotherapy (mDCS) in patients with unresectable metastatic gastric cancer.
Phase 2
Recruiting
- Conditions
- Gastric cancer
- Registration Number
- JPRN-UMIN000002361
- Lead Sponsor
- Tokushima-Hokkaido cancer therapy clinical trial group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of hypersensitivity to DCS. 2)Contraindication to TXT, CDDP, S-1, G-CSF. 3)Infectious disease. 4)Severe compliaction. 5)Neuropathy greater than grade 2. 6)Brain metastasis with clinical symptoms. 7)Watery diarea. 8)Active double cancer. 9)Persons to be pregnant or to make pregnant.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate
- Secondary Outcome Measures
Name Time Method Overall survival, progression free survival, time to response, duration of response, safety